A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants

References

• World Health Organization. Available from: https://covid19.who.int/.
   Google Scholar
• Wu D, Zhang Y, Tang L, et al. Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the Delta variant: real world study and evidence - China, 2021. China CDC Wkly. 2022;4(4):57–65.
   PubMedGoogle Scholar
• Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884.
   PubMed Web of Science ®Google Scholar
• Kang M, Yan Li YY, Sun L, et al. Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Guangdong, China: A Cohort Study. Ann Intern Med. 2021;175(4):533–540.
   Web of Science ®Google Scholar
• Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1553–1559.
   PubMed Web of Science ®Google Scholar
• Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2462.
   PubMed Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331–2333.
   PubMed Web of Science ®Google Scholar
• Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437–446.
   PubMed Web of Science ®Google Scholar
• Hu Z, Tao B, Li Z, et al. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. Int J Infect Dis. 2022;116:204–209.
   PubMed Web of Science ®Google Scholar
• Godoy P, Romero A, Soldevila N, et al. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Euro Surveill. 2018;23(43).
   PubMedGoogle Scholar
• Organizaiton, W.H. WHO COVID-19: Case Definitions. 2020.
   Google Scholar
• Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2021;116:38–42.
   PubMed Web of Science ®Google Scholar
• Krutikov M, Stirrup O, Nacer-Laidi H, et al. COVID-19 Genomics UK consortium. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study. Lancet Healthy Longev. 2022;3(5):e347–e355.
   PubMedGoogle Scholar
• Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022;27(9).
   Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100.
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Diez-Domingo J, Arnedo-Pena A, et al. Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. Vaccine. 2012;30(39):5714–5720.
   PubMed Web of Science ®Google Scholar
• Kislaya I, Rodrigues EF, Borges V, et al. Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with Delta and Alpha variants. Emerg Infect Dis. 2022;28(2):331–337.
   PubMed Web of Science ®Google Scholar
• Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12):2108–2110.
   PubMed Web of Science ®Google Scholar
• Pilz S, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911.
   PubMed Web of Science ®Google Scholar
• Sigal A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat Rev Immunol. 2022;22(2):69–71.
   PubMed Web of Science ®Google Scholar
• England, P.H. Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR. 2020.
   Google Scholar